Abbott Schedules Q3 Earnings for Oct 21 With Consensus Forecasting $1.42 EPS
Question
Abbott Schedules Q3 Earnings for Oct 21 With Consensus Forecasting $1.42 EPS
Direct answer
Top-line revenue expansion of 13.52% to $12.91 billion flows through to operating margins for ABT ahead of October 21 reporting. — bullish pressure on ABT via medical device and diagnostics volume expansion flowing to quarterly revenue.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-13
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Abbott Schedules Q3 Earnings for Oct 21 With Consensus Forecasting $1.42 EPS”, revision 1, evidence through 2026-10-13. https://marketontology.com/catalysts/2026-10-13/abbott-schedules-q3-earnings-for-oct-21-with-consensus-forecasting-1-42-eps-f7f67d
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| ABT | ▲Bull | 1–4 weeks | medical device and diagnostics volume expansion flowing to quarterly revenue | 67 |
Abbott Schedules Q3 Earnings for Oct 21 With Consensus Forecasting $1.42 EPS
Top-line revenue expansion of 13.52% to $12.91 billion flows through to operating margins for ABT ahead of October 21 reporting. — bullish pressure on ABT via medical device and diagnostics volume expansion flowing to quarterly revenue.
Projected Q3 EPS of $1.42 (+9.23%) on $12.91B revenue (+13.52%)
- SourceProjected Q3 EPS of $1.42 (+9.23%) on $12.91B revenue (+13.52%)
- TransmissionTop-line revenue expansion of 13.52% to $12.91 billion flows through to operating margins for ABT ahead of October 21 reporting.
- SummaryAbbott closed at $101.82, advancing 2.23% ahead of broader market performance. Third-quarter results scheduled for October 21 feature consensus estimates of $1.42 EPS. Quarterly revenue is projected to reach $12.91 billion, representing 13.52% growth.
- ABTDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- ABT closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ABT price vs. pre-event level
- ABT volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Abbott (ABT) Gains As Market Dips: What You Should Know · equity_research · 2026-10-12
Related catalysts
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-13Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecastABT
- 2026-10-13Abbott Rises 2.23% to $101.82 Ahead of October 21 Q3 Earnings ReleaseABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42ABT
- 2026-10-13Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line GrowthABT IHI XLV+2.53%
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.